FDA Accepts Tirabrutinib NDA for Relapsed/Refractory PCNSL with December 2026 PDUFA Date
The FDA has accepted for filing the New Drug Application for tirabrutinib under the accelerated approval pathway for relapsed or refractory primary central nervous system lymphoma, setting a PDUFA action date of December 18, 2026.